October 2025
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Oncologists Discuss IDH Inhibition Vs Chemo + RT for Grade 2 Glioma
2
ELEVATE Trial: Elacestrant Combos Boost PFS in ER+/HER2- Breast Cancer
3
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
4
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
5
